Theriva Biologics, Inc. (TOVX) Stock Forecast
TOVX analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.00 / 5 from 2 analysts
- Price target
- $2.50 average of analyst targets
- Upside to target
- +1,102.5% from the latest close
- Next earnings
- November 11, 2026
- 52-week range
- $0.17 – $0.41
TOVX analyst ratings
2 analystsNumber of analysts at each rating.
TOVX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TOVX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | −$0.45 | +86.7% | 1 |
| Current fiscal year (2026) | −$0.25 | −$0.25 | −$0.25 | −$2.08 | +88.0% | 1 |
| Next fiscal year (2027) | −$0.20 | −$0.20 | −$0.20 | −$0.25 | +20.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TOVX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $300,000 | $300,000 | $300,000 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 2 |
TOVX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TOVX revenue: reported and forecast
TOVX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.05 | −$0.05 | −$0.05 | −$0.06 | +20.0% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.20 | −$0.20 | −$0.20 | −$0.20 | −$0.25 | +25.0% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.20 | −$0.20 | −$0.20 | −$0.20 | −$0.20 | 0.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TOVX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TOVX beat in 6 of 12.
What analysts expect from TOVX
2 analysts cover Theriva Biologics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.50, 1,102.5% above the latest close of $0.21. Analysts expect earnings of −$0.25 per share for 2026, +88.0% from a year earlier. For 2027 the average estimate is −$0.20 per share. Theriva Biologics beat the EPS estimate in 6 of the last 12 quarters.
Related: TOVX income statement, TOVX key metrics, TOVX chart. See the TOVX stock overview for the latest quote and news.
TOVX forecast FAQ
What is Theriva Biologics's price target?
The average analyst price target for Theriva Biologics is $2.50, 1,102.5% above the latest close of $0.21.
Is Theriva Biologics a buy, hold or sell?
Of 2 analysts covering Theriva Biologics, 1 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Theriva Biologics's EPS forecast?
Analysts forecast −$0.25 per share for 2026 (range −$0.25 to −$0.25); for 2027 the estimate is −$0.20.
What is Theriva Biologics's revenue forecast?
The average revenue estimate for 2026 is $0.3 million, growth of 0.0%.
When does Theriva Biologics report earnings?
Theriva Biologics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
Does Theriva Biologics usually beat earnings estimates?
Theriva Biologics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.